Galectin Therapeutics (GALT) Preferred Shares (2010 - 2026)
Galectin Therapeutics (GALT) posted quarterly Preferred Shares of $480000.0 for Q1 2026, down 4.0% year-over-year from $500000.0 in Q1 2025, and down 2.04% quarter-over-quarter from $490000.0 in Q4 2025.
Powered by 
Analysis
Galectin Therapeutics (GALT) Preferred Shares (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Preferred Shares history runs 17 years deep, the most recent figure standing at $480000.0 for Q1 2026.
- In Q1 2026, Preferred Shares fell 4.0% year-over-year to $480000.0; the TTM figure through Mar 2026 stood at $480000.0 (down 4.0% YoY), while the FY2025 annual figure was $490000.0, down 2.0% from the prior year.
- Preferred Shares for Q1 2026 stood at $480000.0, down from $490000.0 in the prior quarter.
- The five-year high for Preferred Shares was $527000.0 in Q1 2022, with the low at $480000.0 in Q1 2026.
- The 5-year median for Preferred Shares is $500000.0 (2023), against an average of $502176.5.
- The sharpest annual moves came in 2022 and 2026: Preferred Shares changed 0.0% in 2022, then declined 4.0% in 2026.
- Galectin Therapeutics' Preferred Shares stood at $510000.0 in 2022, then dropped by 1.96% to $500000.0 in 2023, then changed by 0.0% to $500000.0 in 2024, then slipped by 2.0% to $490000.0 in 2025, then fell by 2.04% to $480000.0 in 2026.
- Business Quant data shows GALT's Preferred Shares at $480000.0 in Q1 2026, $490000.0 in Q4 2025, and $490000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Galectin Therapeutics | 304.34 Mn | 304.34 Mn | - | 480,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 480,000.00 |
| Mar 31, 2026 | 480,000.00 |
| Dec 31, 2025 | 490,000.00 |
| Sep 30, 2025 | 490,000.00 |
| Jun 30, 2025 | 490,000.00 |
| Mar 31, 2025 | 500,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Mar 31, 2024 | 500,000.00 |
| Dec 31, 2023 | 500,000.00 |
| Sep 30, 2023 | 510,000.00 |
| Jun 30, 2023 | 510,000.00 |
| Mar 31, 2023 | 510,000.00 |
| Dec 31, 2022 | 510,000.00 |
| Sep 30, 2022 | 510,000.00 |
| Jun 30, 2022 | 510,000.00 |
| Mar 31, 2022 | 527,000.00 |
| Dec 31, 2021 | 527,000.00 |
| Sep 30, 2021 | 527,000.00 |